Table 1 Combination index (CI) values quantified synergism after treatment with PAWI-2 and erlotinib or bortezomib in FG and FGβ3 cells.

From: PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin β3-KRAS-dependent pancreatic cancer stem cells

Cell lines

Drug/Comboa

CIb values at different EDsc

ED75

ED90

ED95

FG

Erlotinib + Bortezomib

0.51d

0.56d

0.59d

 

Erlotinib + PAWI-2

0.64d

0.74d

0.86d

 

Bortezomib + PAWI-2

1.56

1.50

1.47

FGβ3

Erlotinib + Bortezomib

0.87d

1.07

1.19

 

Erlotinib + PAWI-2

0.45d

0.32d

0.25d

 

Bortezomib + PAWI-2

1.55

1.59

1.63

  1. aRatios of Erlotinib:Bortezomib, Erlotinib:PAWI-2 and Bortezomib:PAWI-2 were 50:1, 50:1 and 1:1, respectively;
  2. bCombination Index (CI) values were calculated based on the Chou-Talalay method; values of CI < 1, = 1 and > 1 indicate synergism, additive and antagonism, respectively;
  3. cED75, 90, 95 represent concentrations that cause 75%, 90% and 95% of proliferation inhibition, respectively;
  4. dBold values show synergy.
Back to article page